{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:09:00Z","timestamp":1762506540777},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2015,5,3]],"date-time":"2015-05-03T00:00:00Z","timestamp":1430611200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Tumor Biol."],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1007\/s13277-015-3485-0","type":"journal-article","created":{"date-parts":[[2015,5,2]],"date-time":"2015-05-02T04:47:58Z","timestamp":1430542078000},"page":"7717-7723","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["CD56-negative extranodal NK\/T cell lymphoma should be regarded as a distinct subtype with poor prognosis"],"prefix":"10.1007","volume":"36","author":[{"given":"Liang","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhong-jun","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-qiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,5,3]]},"reference":[{"key":"3485_CR1","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D, International TCLP. International peripheral t-cell and natural killer\/t-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26:4124\u201330.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"3485_CR2","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1158\/1078-0432.CCR-08-2914","volume":"15","author":"YX Li","year":"2009","unstructured":"Li YX, Liu QF, Fang H, Qi SN, Wang H, Wang WH, et al. Variable clinical presentations of nasal and Waldeyer ring natural killer\/t-cell lymphoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2009;15:2905\u201312.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"3485_CR3","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s12185-012-1174-y","volume":"96","author":"L Wang","year":"2012","unstructured":"Wang L, Xia ZJ, Huang HQ, Lu Y, Zhang YJ. Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in the treatment of stage IE\/IIE extranodal natural killer\/t cell lymphoma, nasal type: 13-year follow-up in 135 patients. Int J Hematol. 2012;96:617\u201323.","journal-title":"Int J Hematol"},{"key":"3485_CR4","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.3109\/10428194.2013.827789","volume":"55","author":"L Jiang","year":"2014","unstructured":"Jiang L, Li SJ, Jiang YM, Long JX, Wang RS, Su J, et al. The significance of combining radiotherapy with chemotherapy for early stage extranodal natural killer\/t-cell lymphoma, nasal type: a systematic review and meta-analysis. Leuk Lymphoma. 2014;55:1038\u201348.","journal-title":"Leuk Lymphoma"},{"key":"3485_CR5","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1007\/s12032-014-0860-4","volume":"31","author":"L Wang","year":"2014","unstructured":"Wang L, Wang WD, Xia ZJ, Zhang YJ, Xiang J, Lu Y. Combination of gemcitabine, l-asparaginase, and oxaliplatin (GELOX) is superior to EPOCH or CHOP in the treatment of patients with stage IE\/IIE extranodal natural killer\/t cell lymphoma: a retrospective study in a cohort of 227 patients with long-term follow-up. Med Oncol. 2014;31:860.","journal-title":"Med Oncol"},{"key":"3485_CR6","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/ajh.21256","volume":"83","author":"B Wang","year":"2008","unstructured":"Wang B, Li XQ, Ma X, Hong X, Lu H, Guo Y. Immunohistochemical expression and clinical significance of P-glycoprotein in previously untreated extranodal NK\/T-cell lymphoma, nasal type. Am J Hematol. 2008;83:795\u20139.","journal-title":"Am J Hematol"},{"key":"3485_CR7","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1200\/JCO.2011.35.6287","volume":"29","author":"M Yamaguchi","year":"2011","unstructured":"Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)\/T-cell lymphoma, nasal type: the NK-cell tumor study group study. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29:4410\u20136.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"3485_CR8","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/cncr.27752","volume":"119","author":"L Wang","year":"2013","unstructured":"Wang L, Wang ZH, Chen XQ, Li YJ, Wang KF, Xia YF, et al. First-line combination of gemcitabine, oxaliplatin, and l-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE\/IIE extranodal natural killer\/T-cell lymphoma. Cancer. 2013;119:348\u201355.","journal-title":"Cancer"},{"key":"3485_CR9","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2010-09-307454","volume":"117","author":"A Jaccard","year":"2011","unstructured":"Jaccard A, Gachard N, Marin B, Rogez S, Audrain M, Suarez F, et al. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK\/T-cell lymphoma, a phase 2 study. Blood. 2011;117:1834\u20139.","journal-title":"Blood"},{"key":"3485_CR10","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1756-8722-6-44","volume":"6","author":"N Lin","year":"2013","unstructured":"Lin N, Song Y, Zheng W, Tu M, Xie Y, Wang X, et al. A prospective phase II study of L-asparaginase- CHOP plus radiation in newly diagnosed extranodal NK\/T-cell lymphoma, nasal type. J Hematol Oncol. 2013;6:44.","journal-title":"J Hematol Oncol"},{"key":"3485_CR11","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0037-1963(03)00132-X","volume":"40","author":"ES Jaffe","year":"2003","unstructured":"Jaffe ES, Krenacs L, Raffeld M. Classification of cytotoxic T-cell and natural killer cell lymphomas. Semin Hematol. 2003;40:175\u201384.","journal-title":"Semin Hematol"},{"key":"3485_CR12","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1002\/(SICI)1097-0142(19960515)77:10<2137::AID-CNCR27>3.0.CO;2-V","volume":"77","author":"Y Harabuchi","year":"1996","unstructured":"Harabuchi Y, Imai S, Wakashima J, Hirao M, Kataura A, Osato T, et al. Nasal T-cell lymphoma causally associated with Epstein-Barr virus: clinicopathologic, phenotypic, and genotypic studies. Cancer. 1996;77:2137\u201349.","journal-title":"Cancer"},{"key":"3485_CR13","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/(SICI)1097-0215(19990611)81:6<865::AID-IJC5>3.0.CO;2-S","volume":"81","author":"M Ohsawa","year":"1999","unstructured":"Ohsawa M, Nakatsuka S, Kanno H, Miwa H, Kojya S, Harabuchi Y, et al. Immunophenotypic and genotypic characterization of nasal lymphoma with polymorphic reticulosis morphology. Int J Cancer. 1999;81:865\u201370.","journal-title":"Int J Cancer"},{"key":"3485_CR14","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/j.1365-2559.2004.01867.x","volume":"44","author":"YH Ko","year":"2004","unstructured":"Ko YH, Cho EY, Kim JE, Lee SS, Huh JR, Chang HK, et al. NK and NK-like T-cell lymphoma in extranasal sites: a comparative clinicopathological study according to site and EBV status. Histopathology. 2004;44:480\u20139.","journal-title":"Histopathology"},{"key":"3485_CR15","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1002\/1097-0142(20001115)89:10<2106::AID-CNCR11>3.0.CO;2-G","volume":"89","author":"YH Ko","year":"2000","unstructured":"Ko YH, Ree HJ, Kim WS, Choi WH, Moon WS, Kim SW. Clinicopathologic and genotypic study of extranodal nasal-type natural killer\/T-cell lymphoma and natural killer precursor lymphoma among Koreans. Cancer. 2000;89:2106\u201316.","journal-title":"Cancer"},{"key":"3485_CR16","first-page":"1097","volume":"17","author":"SB Ng","year":"2004","unstructured":"Ng SB, Lai KW, Murugaya S, Lee KM, Loong SL, Fook-Chong S, et al. Nasal-type extranodal natural killer\/T-cell lymphomas: a clinicopathologic and genotypic study of 42 cases in Singapore. Mod Pathol Off J U S Can Acad Pathol Inc. 2004;17:1097\u2013107.","journal-title":"Mod Pathol Off J U S Can Acad Pathol Inc"},{"key":"3485_CR17","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3109\/10428194.2010.543718","volume":"52","author":"YX Li","year":"2011","unstructured":"Li YX, Wang H, Feng XL, Liu QF, Wang WH, Lv N, et al. Immunophenotypic characteristics and clinical relevance of CD56+ and CD56- extranodal nasal-type natural killer\/T-cell lymphoma. Leuk Lymphoma. 2011;52:417\u201324.","journal-title":"Leuk Lymphoma"},{"key":"3485_CR18","doi-asserted-by":"crossref","first-page":"4044","DOI":"10.1200\/JCO.2012.45.5709","volume":"30","author":"B Breuer","year":"2012","unstructured":"Breuer B, Cruciani RA, Portenoy RK. Reply to H. Charalambous et al. J Clin Oncol. 2012;30:4044.","journal-title":"J Clin Oncol"},{"key":"3485_CR19","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3109\/10428194.2011.561388","volume":"52","author":"H Huang","year":"2011","unstructured":"Huang H, Lin Z, Lin X, Cai Q, Xia Z, Jiang W. Long-term outcomes of patients with newly diagnosed extranodal natural killer\/T-cell lymphoma treated by etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin regimen: a single-institution experience. Leuk Lymphoma. 2011;52:1041\u20138.","journal-title":"Leuk Lymphoma"},{"key":"3485_CR20","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group. J Clin Oncol Off J Am Soc Clin Oncol. 1999;17:1244.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"3485_CR21","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.it.2010.08.003","volume":"31","author":"NK Bjorkstrom","year":"2010","unstructured":"Bjorkstrom NK, Ljunggren HG, Sandberg JK. CD56 negative NK cells: origin, function, and role in chronic viral disease. Trends Immunol. 2010;31:401\u20136.","journal-title":"Trends Immunol"},{"key":"3485_CR22","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1182\/blood-2006-07-033142","volume":"109","author":"C Bossard","year":"2007","unstructured":"Bossard C, Belhadj K, Reyes F, Martin-Garcia N, Berger F, Kummer JA, et al. Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK\/T-cell lymphoma: results of a western series of 48 patients treated with first-line polychemotherapy within the groupe d\u2019etude des lymphomes de l\u2019adulte (GELA) trials. Blood. 2007;109:2183\u20139.","journal-title":"Blood"},{"key":"3485_CR23","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1200\/JCO.2005.04.1384","volume":"24","author":"J Lee","year":"2006","unstructured":"Lee J, Suh C, Park YH, Ko YH, Bang SM, Lee JH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24:612\u20138.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"}],"container-title":["Tumor Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-015-3485-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13277-015-3485-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-015-3485-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T15:29:21Z","timestamp":1559489361000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13277-015-3485-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,3]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["3485"],"URL":"https:\/\/doi.org\/10.1007\/s13277-015-3485-0","relation":{},"ISSN":["1010-4283","1423-0380"],"issn-type":[{"value":"1010-4283","type":"print"},{"value":"1423-0380","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,3]]}}}